The Initiative for Medicines, Access, and Knowledge (I-MAK), a public interest team of attorneys and scientists who seek to ensure that patents do not obstruct patient access to affordable medicines, has issued a new report that details the number of patents drug makers have attempted to secure for the highest-grossing drugs in the United States.
The Initiative for Medicines, Access, and Knowledge (I-MAK), a public interest team of attorneys and scientists who seek to ensure that patents do not obstruct patient access to affordable medicines, has issued a new report that details the number of patents drug makers have attempted to secure for the highest-grossing drugs in the United States.
Drawing on data from drug makers’ own reports, patent databases, and IQVIA data, I-MAK found that the 12 top-selling drugs in the United States during 2017 included the high-cost biologics Humira (adalimumab), Rituxan (rituximab), Enbrel (etanercept), Herceptin (trastuzumab), Remicade (infliximab), and Avastin (bevacizumab), all of which are targeted by biosimilar developers. These products cost the US health system a total of $96 billion in 2017.
On average, the sponsors of these drugs attempted to secure 125 patents per product (range, 48-247), with the United States granting an average of 71 patents per drug (range, 27-132). According to I-MAK, these patents “are filed with a strategic intent to extend the commercial monopolies far beyond the intended [20] years of protection,” and have resulted in an average of an additional 38 years of market exclusivity per drug. This lack of competition, says the report, has allowed companies to raise their prices by an average of 68% per product since 2012.
I-MAK calls AbbVie “the worst patent offender,” having both attempted 247 patents for its Humira and raised prices by 144% since 2012. Amgen was not far behind, having raised prices on its Enbrel by 155% in the same time period, though it attempted far fewer patents (57). Roche raised its prices on Avastin by 16%, and sought to gain 219 patents for its product.
The only product for which a price decrease (—58%) was observed since 2012 was Roche and Genentech’s Herceptin, though I-MAK notes that patents pending for the drug could extend its market exclusivity until 2033.
In order to allow for price competition for these high-grossing drugs, concludes the report, the United States will need “significant policy reform.”
In an interview with The Center for Biosimilars® earlier in 2018, Tahir Amin, DipLP, the cofounder and director of intellectual property for I-MAK, said that one key way to reform the US system is to improve upon the standard of what can be patented.
“I feel the law has not kept up with the advances with how [research and development, R&D] is done, and how scientific knowledge has been accumulated over the last 50 years,” said Amin. He explained that, “In order to get your patent, you’re judged by whether it’s novel, based on what’s known in the field, or if it is obvious to someone in the field. The obviousness standard is not applied in the correct way. It’s almost as if techniques from 50 years ago are still not obvious to people, and I think the law hasn’t kept up.”
Among I-MAK’s goals, Amin said, is “…bringing that standard up to where science is today, and we’ll find that a lot of things are obvious. Patents would not be granted so readily, and only the really high-end inventions would be [patentable]. That’s where a lot of the focus needs to be on.”
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.